STIVARGA® (regorafenib) is an approved option after imatinib and sunitinib in patients with locally advanced, unresectable, or metastatic GIST1

  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) list regorafenib (STIVARGA) as a potential treatment option for patients with disease progression (generalized) on imatinib and sunitinib in patients with PS 0-2 (Category 1)1

Potential treatment algorithms1*

STIVARGA (regorafenib) potential treatment chart. Visit hcp.stivarga- us.com to see full safety and Prescribing Information, including Boxed Warning.

National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastrointestinal Stromal Tumors (GISTs) V.1.2021. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

There are limited treatment options for patients with locally advanced, unresectable, or metastatic GIST who have progressed after treatment with 2 tyrosine kinase inhibitors (TKIs)2